胸腺肽α1联合比阿培南治疗重症肺炎患者的疗效

doi:10.3760/cma.j.cn441417-20241128-05016

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (5): 784-787.DOI: 10.3760/cma.j.cn441417-20241128-05016

胸腺肽α1联合比阿培南治疗重症肺炎患者的疗效

吴成琳¹ 王绍霞² 任乐豪³

¹西安大兴医院呼吸科，西安 710016；²西安凤城医院呼吸科，西安 710038；³华中科技大学同济医学院附属协和医院重症医学科，武汉 430023

收稿日期:2024-11-28 出版日期:2025-03-01 发布日期:2025-03-14
通讯作者: 王绍霞，Email：18091283533@163.com
基金资助:
国家自然科学基金青年项目（82000022）

Efficacy of thymic peptide α1 combined with biapenem in the treatment of severe pneumonia

Wu Chenglin¹, Wang Shaoxia², Ren Lehao³

¹Department of Respiratory Medicine, Xi'an Daxing Hospital, Xi'an 710016, China; ²Department of Respiratory Medicine, Xi'an Fengcheng Hospital, Xi'an 710038, China; ³Department of Critical Care Medicine, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China

Received:2024-11-28 Online:2025-03-01 Published:2025-03-14
Contact: Wang Shaoxia, Email: 18091283533@163.com
Supported by:
National Natural Science Foundation of China (82000022)

摘要/Abstract

摘要：

目的　探究胸腺肽α1联合比阿培南对重症肺炎患者的治疗效果及血清CD40L、表面活性蛋白（SP-D）、白细胞介素-1β（IL-1β）的影响。方法　采用前瞻性研究，选取2022年6月至2023年8月西安凤城医院收治的88例重症肺炎患者作为研究对象，根据随机数字表法分为研究组和对照组，各44例。对照组：男24例、女20例，年龄40～69（52.34±5.76）岁；病程1～3（2.10±0.24）周；在常规治疗基础上使用比阿培南（0.3 g+100 ml生理盐水稀释后静脉滴注，每8 h 1次，3次/d）。研究组：男23例、女21例，年龄41～65（50.83±5.24）岁；病程1～4（2.57±0.84）周；在对照组基础上使用胸腺肽α1（1.6 mg胸腺肽α1以1 ml注射用水溶解后皮下注射，每天1次）。两组患者均持续治疗2周。比较两组患者治疗有效率，治疗前后急性生理学和慢性健康状况评价Ⅱ（APACHEⅡ）评分，以及血清CD40L、SP-D、IL-1β水平。统计学方法采用t检验、χ²检验。结果　研究组治疗有效率高于对照组［84.91%（37/44）比70.45%（31/44）］，差异有统计学意义（χ²=4.706，P<0.05）。治疗后，研究组APACHEⅡ评分和CD40L、IL-1β、SP-D水平均低于对照组［（12.59±4.35）分比（15.40±4.61）分、（1.48±0.63）μg/L比（2.64±0.40）μg/L、（19.81±1.57）ng/L比（24.30±1.76）ng/L、（145.67±10.69）μg/L比（152.31±10.74）μg/L］，差异均有统计学意义（t=-2.943、-10.361、-12.653、-2.912，均P<0.05）。结论　胸腺肽α1联合比阿培南能提高重症肺炎患者治疗效果，改善临床症状，降低血清CD40L、SP-D、IL-1β水平。

关键词:

重症肺炎, 胸腺肽α1, 比阿培南, 疗效

Abstract:

Objective　To investigate the therapeutic effect of thymic peptide α1 combined with biapenem in the treatment of severe pneumonia and its effects on serum CD40L, surfactant associated protein D (SP-D), and interleukin-1β (IL-1β) levels. Methods　In this prospective study, 88 patients with severe pneumonia admitted to Xi'an Fengcheng Hospital from June 2022 to August 2023 were selected as the research objects, and were divided into a study group and a control group according to the random number table method, with 44 cases in each group. In the control group, there were 24 males and 20 females, aged 40-69 (52.34±5.76) years, and the course of disease was 1-3 (2.10±0.24) weeks. In the study group, there were 23 males and 21 females, aged 41-65 (50.83±5.24) years, and the course of disease was 1-4 (2.57±0.84) weeks. The control group was given biapenem on the basis of conventional treatment (intravenous drip with 0.3 g diluted in 100 ml of normal saline, once every 8 h, 3 times a day). The study group was given thymic peptide α1 on the basis of the control group (1.6 mg thymic peptide α1 was dissolved in 1 ml of water for injection and then injected subcutaneously, once a day). Both groups were treated for 2 weeks. The effective rate of treatment, Acute Physiology and Chronic Health Evaluation Ⅱ (APACHEⅡ) score, and serum levels of CD40L, SP-D, and IL-1β were compared between the two groups. t test and χ² test were used for statistical analysis. Results　The effective rate of treatment in the study group was higher than that in the control group [84.91% (37/44) vs. 70.45% (31/44)], with a statistically significant difference (χ²=4.706, P<0.05). After treatment, the APACHEⅡ score and levels of CD40L, IL-1β, and SP-D in the study group were lower than those in the control group [(12.59±4.35) points vs. (15.40±4.61) points, (1.48±0.63) μg/L vs. (2.64±0.40) μg/L, (19.81±1.57) ng/L vs. (24.30±1.76) ng/L, (145.67±10.69) μg/L vs. (152.31±10.74) μg/L], with statistically significant differences (t=-2.943, -10.361, -12.653, and -2.912, all P<0.05). Conclusion　Thymic peptide α1 combined with biapenem can improve the therapeutic effect and clinical symptoms of severe pneumonia, and reduce serum CD40L, SP-D, and IL-1β levels.

Key words:

Severe pneumonia, Thymic peptide α1, Biapenem, Curative effect

吴成琳王绍霞任乐豪.

胸腺肽α1联合比阿培南治疗重症肺炎患者的疗效 [J]. 国际医药卫生导报, 2025, 31(5): 784-787.

Wu Chenglin, Wang Shaoxia, Ren Lehao.

Efficacy of thymic peptide α1 combined with biapenem in the treatment of severe pneumonia [J]. International Medicine and Health Guidance News, 2025, 31(5): 784-787.

参考文献

[1] 王晓,张玉玲. 婴儿社区获得性肺炎进展为重症肺炎预警指标的研究现状[J]. 妇儿健康导刊,2024,3(19):21-24.
[2] 郑玉君,王茜,秦克,等. ICU重症肺炎用药后鲍曼不动杆菌定植检出率及对病死率的影响[J]. 疑难病杂志,2020,19(6):603-606. DOI:10.3969/j.issn.1671-6450.2020.06.016.
[3] 彭建新,任方. 小儿重症肺炎的临床特征及预后影响因素分析[J]. 临床医学研究与实践,2021,6(20):40-42. DOI:10.19347/j.cnki.2096-1413.202120011.
[4] 倪俊杰,张妮,张烨. 比阿培南联合头孢他啶对泛耐药鲍曼不动杆菌的抗菌活性分析[J]. 中国现代药物应用,2024,18(8):84-87. DOI:10.14164/j.cnki.cn11-5581/r.2024. 08.022.
[5] 钟晓莉,余林,邓海波,等. 236例ICU呼吸机相关性肺炎患者病原菌分布及耐药性分析[J]. 中国病原生物学杂志,2024,19(7):838-841. DOI:10.13350/j.cjpb.240719.
[6] 李伟雄. 某中医院重症肝病患者并发医院感染的病原菌分布与耐药性分析[J]. 抗感染药学,2024,21(5):537-540. DOI:10.13493/j.issn.1672-7878.2024.05-024.
[7] 王旭. 胸腺肽α1联合抗生素治疗肺结核的临床效果分析[J]. 中国社区医师,2024,40(26):37-39. DOI:10.3969/j.issn.1007-614x.2024.26.013.
[8] 中华医学会呼吸病学分会. 社区获得性肺炎诊断和治疗指南[J]. 中华结核和呼吸杂志,2006,29(10):651-655. DOI:10.3760/j:issn:1001-0939.2006.10.002.
[9] 李游,田伟盟,武祺,等. 中西医结合治疗100例老年重症肺炎的临床疗效分析[J]. 中国危重病急救医学,2011,23(1):44-45. DOI:10.3760/cma.j.issn.1003-0603.2011.01.012.
[10] 刘辉,王运,甘文云,等. 胸腺肽辅助比阿培南对老年重症肺炎患者肺功能的影响[J]. 实用中西医结合临床,2021,21(19):14-16. DOI:10.13638/j.issn.1671-4040.2021. 19.006.
[11] 白璐,金兆辰,侯雯跻. 胸腺肽α1联合抗感染药物治疗重症肺炎患者的效果观察[J/CD]. 现代医学与健康研究(电子版),2024,8(13):50-52. DOI:10.3969/j.issn.2096-3718. 2024.13.016.
[12] 周文霞. 重组人粒细胞刺激因子、胸腺肽α1治疗老年重症肺炎疗效[J]. 山西卫生健康职业学院学报,2024,34(4):58-60.
[13] 伍庭林,周秋明,伍廷平,等. 抗痨解毒方联合胸腺肽α1治疗肺结核(肺脾气虚型)对T淋巴细胞亚群及痰菌转阴的影响[J]. 四川中医,2023,41(1):80-84.
[14] 郑晓栗,暨永亮,林捷. 比阿培南联合氨溴索治疗高龄重症肺炎的疗效及对炎性因子的影响[J]. 临床合理用药,2024,17(30):51-54. DOI:10.15887/j.cnki.13-1389/r.2024. 30.014.
[15] 王静,汤昱,赵二要,等. 血清SP-D、IL-17、IL-33与重症肺炎患儿肺损伤程度的关系及判断预后的价值[J]. 医学研究杂志,2022,51(6):89-92,27. DOI:10.11969/j.issn.1673- 548X.2022.06.020.
[16] 张素婷,许银银. IL-1β和IL-18对重症肺炎的诊断意义[J]. 中国现代医生,2024,62(13):36-39,78. DOI:10.3969/j.issn.1673-9701.

胸腺肽α1联合比阿培南治疗重症肺炎患者的疗效

Efficacy of thymic peptide α1 combined with biapenem in the treatment of severe pneumonia

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王纪科刘锦波. 钬激光与铥激光剜除术治疗良性前列腺增生疗效及安全性的meta分析 [J]. 国际医药卫生导报, 2025, 31(6): 930-939.
[2]	思雅芳刘瑜瑜曹丽. 不同剂量利妥昔单抗治疗特发性膜性肾病的效果及复发影响因素分析 [J]. 国际医药卫生导报, 2025, 31(5): 723-728.
[3]	郭桂军刘佛林. 新辅助治疗联合根治性膀胱切除术治疗肌层浸润性膀胱癌的效果 [J]. 国际医药卫生导报, 2025, 31(5): 742-745.
[4]	张鹏娟宁芳卫张中冕范林鹏. 肺叶定量CT参数和HCAR水平与慢性阻塞性肺疾病患者病情程度及疗效的相关性 [J]. 国际医药卫生导报, 2025, 31(5): 779-783.
[5]	宋群莉关微陈瑶莉. 信迪利单抗联合沙利度胺治疗中晚期食管癌的临床研究 [J]. 国际医药卫生导报, 2025, 31(5): 806-810.
[6]	高好好李朋菊宋虎杰. 依达拉奉联合醒脑静注射液对蛛网膜下腔出血患者神经功能的临床效果 [J]. 国际医药卫生导报, 2025, 31(4): 608-612.
[7]	钟意敏李文芳黄焕容郑洁如冼海燕. 背部低频电刺激配合如意金黄散和手法按摩治疗哺乳期急性乳腺炎患者的疗效观察 [J]. 国际医药卫生导报, 2025, 31(4): 618-622.
[8]	张愉张恺铄曹洪友高山. 尼妥珠单抗靶向治疗局部晚期鼻咽癌患者的临床疗效观察 [J]. 国际医药卫生导报, 2025, 31(4): 669-673.
[9]	刘功艳王琳李传波韩克丽. 尼可地尔联合胺碘酮对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响 [J]. 国际医药卫生导报, 2025, 31(3): 382-386.
[10]	关微焦建虎陈娟李秋云魏当. 西格列他钠联合重组人胰岛素对2型糖尿病患者的治疗效果 [J]. 国际医药卫生导报, 2025, 31(3): 478-482.
[11]	杨娟钱佳齐. 冷沉淀凝血因子联合氨甲环酸在颅脑创伤性凝血功能障碍患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(2): 308-312.
[12]	王文斌郭小花郑兆华郭曼孙力. 帕博利珠单抗联合白蛋白紫杉醇与卡培他滨方案治疗进展期胃癌患者的疗效评估 [J]. 国际医药卫生导报, 2024, 30(9): 1430-1434.
[13]	朱补全李余良. 酒石酸美托洛尔联合胺碘酮治疗急性心肌梗死心律失常的疗效观察 [J]. 国际医药卫生导报, 2024, 30(8): 1273-1278.
[14]	杨格王丹丹. 无创呼吸机治疗重症急性左心心力衰竭的疗效分析 [J]. 国际医药卫生导报, 2024, 30(8): 1278-1281.
[15]	于菁菁邵琛曲朋张老追. 不同日剂量美罗培南在肾功能亢进患者中的临床疗效 [J]. 国际医药卫生导报, 2024, 30(8): 1321-1325.